In Brief: FDA Division of Bioequivalence
FDA Division of Bioequivalence: Rabindra Patnaik, PhD, is acting director. The Feb. 27 issue of "The Pink Sheet" (In Brief) incorrectly identified the current acting director of the division in the Office of Generic Drugs. Agnes Wu, PhD, served as acting division director from December 1992-April 1993 followed by permanent director Shrikant Dighe who retired in March 1994. When Ciba-Geigy's Keith Chan, PhD, becomes division director April 17, Patnaik will become deputy director...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth